Hofstra W, de Vries-Hospers H G, van der Waaij D
Infection. 1979;7(4):166-70. doi: 10.1007/BF01640934.
Nystatin was administered in ten healthy adult volunteers in increasing doses of 3 X 10(6) I U, 6 X 10(6) I U, 9 X 10(6) I U and 12 X 10(6) I U per day, each dose being given for a five-day period. Faecal samples were collected daily for the determination of their concentration of biologically active nystatin. Nystatin concentrations were determined biologically; the sensitivity of this method was less than or equal to 20 mcg/g of faeces. During the four treatment periods with increasing doses, 38%, 31%, 26% and 20% respectively of the faecal samples contained biologically undetectable amounts of nystatin. This means that nystatin is either inactivated or unevenly distributed through the intestinal contents, or both. The practical consequences of this may be that in a significant portion of the colon there is no inhibitory nystatin concentration against Candida albicans, despite treatment with as much as 12 X 10(6) I U of nystatin per day.
对10名健康成年志愿者服用制霉菌素,剂量逐日增加,分别为每日3×10⁶国际单位、6×10⁶国际单位、9×10⁶国际单位和12×10⁶国际单位,每个剂量服用5天。每天收集粪便样本以测定其中生物活性制霉菌素的浓度。制霉菌素浓度采用生物学方法测定;该方法的灵敏度小于或等于20微克/克粪便。在剂量递增的四个治疗期内,粪便样本中分别有38%、31%、26%和20%含有生物学检测不到的制霉菌素量。这意味着制霉菌素要么被灭活,要么在肠道内容物中分布不均,或者两者皆有。这一情况的实际后果可能是,尽管每天服用高达12×10⁶国际单位的制霉菌素进行治疗,但在相当一部分结肠中,不存在对白色念珠菌有抑制作用的制霉菌素浓度。